PharmiNews

The Directory of Pharma Companies and News

Biomarin

Biomarin logo
BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises five approved products and multiple clinical and pre-clinical product candidates. Approved products include Vimizim® (elosulfase alfa) for MPS IVA, a product wholly developed and commercialized by BioMarin; Naglazyme® (galsulfase) for MPS VI, a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for MPS I, a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Powder for Oral Solution and Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany and Firdapse® (amifampridine), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include drisapersen, an exon skipping oligonucleotide, for which a marketing application has been submitted to FDA for the treatment of patients with Duchenne muscular dystrophy (DMD) with mutations in the dystrophin gene that are amenable to treatment with exon 51 skipping, pegvaliase (PEGylated recombinant phenylalanine ammonia lyase, formerly referred to as BMN 165 or PEG PAL), which is currently in Phase 3 clinical development for the treatment of PKU, talazoparib (formerly referred to as BMN 673), a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase 3 clinical development for the treatment of germline BRCA breast cancer, reveglucosidase alfa (formerly referred to as BMN 701), a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase 3 clinical development for the treatment of Pompe disease, vosoritide (formerly referred to as BMN 111), a modified C-natriuretic peptide, which is currently in Phase 2 clinical development for the treatment of achondropl
Category: Pharmaco
Category: Pharmaco

Biomarin News

DateNews
2017-08-07BioMarin Announces Offering of $450 Million of 0.599% Senior Subordinated Convertible Notes Due 2024
2017-08-07BioMarin Announces Offering of $450 Million of Senior Subordinated Convertible Notes Due 2024
2017-08-02BioMarin Announces Second Quarter 2017 Financial Results
2017-08-02BioMarin Announces Plans to Progress Both the 6e13vg/kg and 4e13 vg/kg Doses of BMN 270, its Investigational Gene Therap...
2017-07-31BioMarin to Host Second Quarter 2017 Financial Results Conference Call and Webcast on Wednesday, August 2 at 4:30pm ET
2017-07-18BioMarin to Host Second Quarter 2017 Financial Results Conference Call and Webcast on Wednesday, August 2 at 4:30pm ET
2017-07-18Sarepta Therapeutics and BioMarin Pharmaceutical Inc. Announce Execution of a Global Settlement and a License Agreement ...
2017-07-11BioMarin's Investigational Gene Therapy for Hemophilia A at 6e13 vg/kg Dose Maintains Average Factor VIII Levels within ...
2017-06-30BioMarin Submits Pegvaliase Biologics License Application (BLA) to the U.S. FDA for Treatment of Phenylketonuria (PKU)
2017-06-16BioMarin Announces Acceptance of Late Breaking Abstract at the International Society on Thrombosis and Haemostasis 2017 ...
2017-06-01European Commission Approves Brineura™ (cerliponase alfa), the First Treatment for CLN2 Disease, a Form of Batten Diseas...
2017-05-31BioMarin to Attend Upcoming Investor Conference
2017-05-04BioMarin Announces First Quarter 2017 Financial Results
2017-05-02BioMarin to Attend Two Upcoming Investor Conferences
2017-04-27FDA Approves Brineura™ (cerliponase alfa) for the Treatment of CLN2 Disease, a Form of Batten Disease and Ultra-Rare Ped...
2017-04-21BioMarin Receives Positive CHMP Opinion in Europe for Brineura™ (cerliponase alfa) for First Treatment of CLN2 Disease, ...
2017-04-20BioMarin to Host First Quarter 2017 Financial Results Conference Call and Webcast on Thursday, May 4 at 4:30pm ET
2017-04-13BioMarin Announces Kuvan® (sapropterin dihydrochloride) Patent Challenge Settlement
2017-02-23BioMarin Announces Fourth Quarter and Full Year 2016 Financial Results
2017-02-15BioMarin Announces 11 Presentations at 13th Annual WORLDSymposium™ 2017
2017-02-08BioMarin to Attend Three Investor Conferences in 1Q17
2017-02-07BioMarin to Host Fourth Quarter and Full Year 2016 Financial Results Conference Call and Webcast on Thursday, February 2...
2017-02-01BioMarin Receives Access to Priority Medicines (PRIME) Regulatory Support from EMA for BMN 270 Gene Therapy in Hemophili...
2017-01-08BioMarin to Provide Update to Proof-of-Concept Data for BMN 270 Gene Therapy in Hemophilia A at 35th Annual J.P. Morgan ...
2017-01-03BioMarin to Present at 35th Annual J.P. Morgan Healthcare Conference in San Francisco
2016-12-12BioMarin Enrolls First Participant in Phase 3 Trial of Vosoritide for Treatment of Children with Achondroplasia
2016-11-03BioMarin to Attend Three Upcoming Investor Conferences
2016-10-27BioMarin Announces Third Quarter 2016 Financial Results
2016-10-19BioMarin Presents Vosoritide Data in Achondroplasia at American Society of Human Genetics (ASHG) 2016 Meeting
2015-10-29BioMarin Announces Third Quarter 2015 Financial Results and Company Update
2015-10-27BioMarin to Attend Upcoming Investor Conference in November
2015-10-15BioMarin Announces FDA Advisory Committee to Review Drisapersen for Treatment of Patients With Duchenne Muscular Dystrop...
2015-10-15BioMarin to Host Third Quarter 2015 Financial Results Conference Call and Webcast on Thursday, October 29 at 4:30pm ET
2015-10-12BioMarin's Initial 6-Month Data from Phase 2 Study of Vosoritide (BMN 111) in Children with Achondroplasia Presented at ...
2015-10-01BioMarin to Acquire Rights to Phenylketonuria (PKU) Franchise From Merck Serono
2015-09-30BioMarin to Present Research Results on Duchenne Muscular Dystrophy and Pompe Disease Programs at the 20th International...
2015-09-29BioMarin Receives Favorable Ruling in the Use of Exon 51 Antisense Oligonucleotides Patent Interference
2015-09-28BioMarin Enrolls First Patient in Phase 1/2 Trial of Gene Therapy Drug Candidate BMN 270 for the Treatment of Hemophilia...
2015-09-18BioMarin Announces Kuvan(R) (sapropterin dihydrochloride) Patent Challenge Settlement
2015-09-02BioMarin to Attend Upcoming Investor Conferences in September
2015-09-01BioMarin Launches kNOWyourDuchenne, Comprehensive Program for Patients With Duchenne Muscular Dystrophy to Understand Th...
2015-08-31BioMarin Announces Two Oral and 19 Poster Presentations at the Society for the Study of Inborn Errors of Metabolism 2015...
2015-08-24Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to Talazoparib (BMN 673), a ...
2015-08-19Forbes Ranks BioMarin 10th Most Innovative Company in the World
2015-08-19BioMarin Receives Rare Pediatric Disease Designation From FDA for Drisapersen for the Potential Treatment of Duchenne Mu...
2015-08-03BioMarin Announces Second Quarter 2015 Financial Results and Company Update
2015-07-27BioMarin Joins the NASDAQ-100 Index
2015-07-20BioMarin Provides Program Update for Talazoparib in Metastatic Breast Cancer
2015-07-15BioMarin to Host Second Quarter 2015 Financial Results Conference Call and Webcast on Monday, August 3 at 4:30pm ET
2015-06-29BioMarin Announces FDA Accepts Drisapersen NDA for Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
2015-06-25BioMarin Announces EMA Validates MAA for Drisapersen for Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Sk...
2015-06-17BMN 111 (vosoritide) Improves Growth Velocity in Children With Achondroplasia in Phase 2 Study
2015-06-15BioMarin CEO Jean-Jacques Bienaime Awarded EY Entrepreneur Of The Year(R) 2015 Award in Northern California in Health an...
2015-06-08BioMarin Submits Drisapersen MAA to EMA for the Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
2015-06-04Jean-Jacques Bienaime, CEO of BioMarin, to Present at the Goldman Sachs 36th Annual Global Healthcare Conference
2015-05-01BioMarin Management to Present at the Deutsche Bank 40th Annual Health Care Conference on May 6th; Bank of America Merri...
2015-04-30BioMarin Announces First Quarter 2015 Financial Results and Company Update
2015-04-27BioMarin Completes Rolling NDA Submission to FDA for Drisapersen for Treatment of Duchenne Muscular Dystrophy Amenable t...
2015-04-23BioMarin Presents Data on Duchenne Muscular Dystrophy at the 67th American Academy of Neurology Annual Meeting
2015-04-14BioMarin to Host First Quarter 2015 Financial Results Conference Call and Webcast on Thursday, April 30 at 4:30pm ET
2015-03-30BioMarin Announces One Oral and 7 Poster Presentations at the 2015 American College of Medical Genetics and Genomics Ann...
2015-03-18BioMarin Pharmaceutical Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2015-02-25BioMarin Announces Fourth Quarter and Full Year 2014 Financial Results
2015-02-20BioMarin Pharmaceutical Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2015-02-10Prosensa Announces Voluntary Delisting and Advance Liquidation Distribution
2015-02-09BioMarin Announces 2 Oral and 8 Poster Presentations at Lysosomal Disease Network's 11th Annual WORLD Symposium(TM)
2015-02-04BioMarin to Attend Upcoming Investor Conferences
2015-02-03BioMarin to Host Fourth Quarter and Full Year 2014 Financial Results Conference Call and Webcast on Wednesday, February ...
2015-01-30BioMarin Announces Final Results of Tender Offer for Prosensa's Shares and Completion of Subsequent Offering Period
2015-01-30Prosensa Announces Intent to Voluntarily Delist From NASDAQ
2015-01-23BioMarin Announces Underwriters' Full Exercise of Option to Purchase Additional Shares
2015-01-22BioMarin Announces Pricing of Public Offering of Common Stock
2015-01-21BioMarin Announces Public Offering of Common Stock
2015-01-15BioMarin Announces Completion of Tender Offer for Prosensa's Shares and Commences Subsequent Offering Period
2015-01-13Prosensa Announces Shareholder Approval of Certain Matters Relating to the BioMarin Tender Offer
2015-01-12BioMarin Provides Preliminary Data From Ongoing Phase 1/2 Pivotal Study of BMN 190 for Treatment of CLN2 Disorder, a For...
2015-01-07BioMarin Announces Planned Changes to Board of Directors Leadership Structure
2015-01-06BioMarin to Present at the J.P. Morgan Healthcare Conference
2014-12-29BioMarin Announces Approval of VIMIZIM(R) (elosulfase alfa) in Japan for Treatment of Morquio A Syndrome
2014-12-24BioMarin and Prosensa Announce Expiration of the Hart-Scott-Rodino Waiting Period for BioMarin's Proposed Acquisition of...
2014-12-10BioMarin's VIMIZIM(R) (elosulfase alfa) Approved in Brazil for Treatment of Morquio A Syndrome
2014-12-10FDA Grants BioMarin Orphan Drug Designation for NAGLU Fusion Protein, BMN 250, for the Treatment of MPS IIIB (Sanfilippo...
2014-12-09BioMarin to Highlight Breadth of Innovative Development Pipeline at Analyst and Investor Day on December 10th in New Yor...
2014-12-07BioMarin's VIMIZIM(R) (elosulfase alfa) Approved in Australia for Treatment of Morquio A Syndrome
1970-01-01Servier and miRagen extend collaboration for the research, development and commercialization of microRNA-targeting thera...
1970-01-01Servier successfully issues euro private placement
1970-01-01Record number of bendamustine abstracts accepted for presentation at the Annual Meeting of the American Society of Hemat... (PDF)
1970-01-01Positive European Commission decision on\n\u003cstrong\u003e \u003cem\u003eflutiform\u003c/em\u003e \u003c/strong\u003e ... (PDF)
1970-01-01Promising results in search for treatment for patients with indolent non-Hodgkin lymphoma (PDF)
Brought to you by PharmiWeb.com - Latest Jobs in Pharma
Brought to you by www.pharmiweb.com - Latest Jobs in Pharma.